Factor VIII is a glycoprotein mainly synthesized by the liver. It circulates in the plasma as bound to vWF which protects it from rapid proteolytic degradation.
It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa.
A patient who is deficient in FVIII has hemophilia A.
FVIII insufficiency as well as FVIII replacement therapy can be monitored. (Specialized hemostasis)
- Linearity: 1 - 144 (activity%).
- Detection limit: 0% (activity%)
- 5 minutes incubation and 3 minutes reading
- End point or kinetic
- 24 hour stability of reagents on analyzers
- Reagents refreezable 14 days at -20 ° C
- Insensitivity of TECHNOCHROM FVIII: C reagent to Emicizumab
- 2 vials of FXa-1 + αNAPAP substrate (2 mL)
- 2 vials x reagent A (Phospholipid, Albumin) (2 mL)
- 2 vials x reagent B (FIXaß, FX, Ca ++ , Albumin, Thrombin) (2 mL)
- 1 bottle x ref. Stand. FVIII 1 (≈ 130%) (1 mL)
- 1 bottle x ref. Stand. FVIII 2 (≈ 70%) (1 mL)
- 1 bottle x ref. Stand. FVIII 3 (≈ 10%) (1 mL)
- 1 bottle x ref. Stand. FVIII 4 (<0.5%) (1 mL)
- 3 vials x FVIII dilution buffer (30 mL)
- 2 vials x FVIII reaction buffer (8 mL)
